Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Proskauer recently released a comprehensive U.S. IPO Analysis. The study examines key factors and aspects of the U.S. IPO market and provides market participants with extensive data about deal structures and terms, SEC comments and timing, financial profiles and accounting disclosures, corporate governance, and expenses. It also includes separate industry sections on health care, TMT, consumer/retail, financial services and industrials. Read the full study here: http://www.proskauer.com/files/uploads/Documents/Proskauer-2014-IPO_Study.pdf
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4534
[post_author] => 4
[post_date] => 2024-04-08 13:47:00
[post_date_gmt] => 2024-04-08 17:47:00
[post_content] =>
The Center for Biotechnology has announced the appointment of Dr. Dee Dao as Associate Director for Business Development and Investment. In her new role, Dr. Dao will serve as the primary contact on issues related to research, technology development and commercialization for the Center for Biotechnology. Additionally, Dr. Dao will foster new collaborative relationships in order to bolster sponsored research agreements and strategic alliances.
Prior to joining the CFB, Dr. Dao served as a Venture Associate for the NYU Innovation Venture Fund, where she focused on investment opportunities in life science and healthcare. Prior to NYU, Dr. Dao was at the Ludwig Institute for Cancer Research where she contributed to early oncology therapeutic development planning and oversaw intellectual property (IP) strategy to support the clinical development of the Institute’s therapeutics. Before that, Dr. Dao investigated bacterial virulence and immunity to identify new vaccines against Tuberculosis as a postdoctoral fellow in an HHMI laboratory at Albert Einstein College of Medicine.
Currently, Dr. Dao also serves as a mentor for entrepreneurs participating in the Entrepreneurship Lab, a NYCEDC initiative. Dr. Dao received a Ph.D. in Molecular Genetics/Developmental Biology at Columbia University and a B.S. in Chemistry from University of Pittsburgh. Dr. Dao is also an alumnus of the Center for Biotechnology’s Fundamentals of the Bioscience Program in 2010.
“We are thrilled to have Dee join the Center for Biotechnology to lead our technology and business development efforts on behalf of innovators and emerging companies in New York” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “Dee brings deep experience working with and funding innovation to her role at the Center which our clients and community will greatly benefit from.”
“I am very happy to join the team at the Center for Biotechnology. I’ve admired the work the Center for Biotechnology has done when it comes to supporting and accelerating the development of biomedical technology in New York State” Dr. Dao said. “I’m looking forward to helping lead the technology and business development efforts of the Center and increase the impact the organization can have on the wealth of innovations in the region”.
[post_title] => Dr. Dee Dao Appointed Associate Director for Business Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dr-dee-dao-appointed-associate-director-for-business-development
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:42:43
[post_modified_gmt] => 2025-02-24 17:42:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4534
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4051
[post_author] => 4
[post_date] => 2023-03-16 14:01:07
[post_date_gmt] => 2023-03-16 14:01:07
[post_content] =>
The NIH is providing an opportunity for grantees to participate in an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies through our commercialization assistance program, Concept to Clinic: Commercializing Innovation Education (e-C3i). This program provides entrepreneurial education for investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The eC3i course is being offered to investigators with active (or in a No-Cost Extension through 9/23) NIH-funded research projects from participating Institutes and Centers.
All applications must be received no later than April 14th, 2023. Apply Today! Applications can be submitted to NIBIB-SBIR@mail.nih.gov. All NHLBI grantees are encouraged to contact us (nhlbi_sbir@mail.nih.gov) if you are interested in participating or have any questions about the application process. Learn more here.
[post_title] => NIH Grantees: Learn How to Commercialize Your Tech
[post_excerpt] => The NIH is providing an opportunity for grantees to participate in an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-ec3i-2023
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:34:34
[post_modified_gmt] => 2024-08-22 15:34:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4051
[menu_order] => 5
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3750
[post_author] => 1
[post_date] => 2021-04-07 19:20:10
[post_date_gmt] => 2021-04-07 19:20:10
[post_content] =>
To accelerate the development of the next generation of masks, BARDA and NIOSH have partnered to launch the Mask Innovation Challenge: Building Tomorrow’s Mask. The Mask Innovation Challenge aims to improve the comfort, utility, and protective capabilities of available community masks that are worn during day-to-day activities when physical distancing is not possible. This competition is designed to support the development of mask designs that meet predefined performance standards, while providing increased comfort and durability to the average consumer.
Can you help build a better mask – one that people are interested in wearing? You will have helped solved one of the biggest problems of the day! The mask design innovation challenge puts up a $500,000 prize purse for new mask designs that overcome the common reasons people don’t wear masks in the current pandemic. Phase 1 is design, due 5 p.m. April 21, 2021; phase 2 is testing of prototypes by NIOSH scientists and partner labs. Learn more at drive.hhs.gov/mask_challenge.html and then see Challenge.gov for the rules, criteria, timelines and how to submit.
Mask Innovation Challenge Event 4/15
Don't miss the Mask Innovation Challenge event at the Venture Café at UCSC on Thursday, April 15, 2021: "Why we need to innovate on the non-medical grade face mask" from 3-4pm EDT. HHS’s Biomedical Advanced Research and Development Authority (BARDA) will discuss comfort, utility, and protective factor of current non-medical grade face masks as well as opportunities to innovate on these designs.
8this link can be used to access the event on the day of the talk, no registration required)
[post_title] => BARDA: Mask Innovation Challenge
[post_excerpt] => Can you help build a better mask – one that people are interested in wearing? The mask design innovation challenge puts up a $500,000 prize purse for new mask designs that overcome the common reasons people don’t wear masks in the current pandemic.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => barda-mask-innovation-challenge
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-20 16:13:51
[post_modified_gmt] => 2021-09-20 16:13:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3750
[menu_order] => 48
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
